uniQure (QURE) Competitors

MorphoSys (NASDAQ:MOR) and uniQure (NASDAQ:QURE) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, community ranking, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Does the MarketBeat Community believe in MOR or QURE?

uniQure received 637 more outperform votes than MorphoSys when rated by MarketBeat users. Likewise, 70.73% of users gave uniQure an outperform vote while only 38.46% of users gave MorphoSys an outperform vote.

Company	Underperform	Outperform
MorphoSys	Outperform Votes 25 38.46%	Underperform Votes 40 61.54%
uniQure	Outperform Votes 662 70.73%	Underperform Votes 274 29.27%

Which has preferable valuation and earnings, MOR or QURE?

MorphoSys has higher revenue and earnings than uniQure. MorphoSys is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	-5.45
uniQure	$20.20M	42.03	-$308.48M	-$4.39	-3.53

Do institutionals & insiders hold more shares of MOR or QURE?

18.4% of MorphoSys shares are held by institutional investors. Comparatively, 78.8% of uniQure shares are held by institutional investors. 0.1% of MorphoSys shares are held by insiders. Comparatively, 4.7% of uniQure shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Which has more risk & volatility, MOR or QURE?

MorphoSys has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Comparatively, uniQure has a beta of 0.1, suggesting that its stock price is 90% less volatile than the S&P 500.

Do analysts rate MOR or QURE?

uniQure has a consensus target price of $37.82, suggesting a potential upside of 143.99%. Given uniQure's stronger consensus rating and higher probable upside, analysts plainly believe uniQure is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
uniQure	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.91

Is MOR or QURE more profitable?

MorphoSys has a net margin of -226.79% compared to uniQure's net margin of -837.80%. uniQure's return on equity of -188.82% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
uniQure	-837.80%	-188.82%	-32.17%

Does the media favor MOR or QURE?

In the previous week, uniQure had 11 more articles in the media than MorphoSys. MarketBeat recorded 11 mentions for uniQure and 0 mentions for MorphoSys. MorphoSys' average media sentiment score of 0.00 beat uniQure's score of -0.19 indicating that MorphoSys is being referred to more favorably in the media.

Company	Overall Sentiment
MorphoSys	Neutral
uniQure	Neutral

Summary

uniQure beats MorphoSys on 12 of the 19 factors compared between the two stocks.